{
    "pmcid": "8928829",
    "qa_pairs": {
        "How was NIH-CoVnb-112 produced for therapeutic applications?": [
            "Expressed in Pichia pastoris",
            "Synthesized chemically",
            "Expressed in Escherichia coli",
            "Produced in mammalian cell culture"
        ],
        "What is the primary target of the nanobody NIH-CoVnb-112 developed for SARS-CoV-2?": [
            "The receptor-binding domain (RBD) of SARS-CoV-2",
            "The nucleocapsid protein of SARS-CoV-2",
            "The spike protein's S2 subunit of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2"
        ],
        "What structural feature stabilizes the interaction between NIH-CoVnb-112 and the SARS-CoV-2 RBD?": [
            "An inter-CDR disulfide bond",
            "A hydrogen bond network",
            "A salt bridge interaction",
            "A hydrophobic pocket"
        ],
        "What was the observed effect of nebulized NIH-CoVnb-112 in the Syrian hamster model?": [
            "Significant reduction in viral burden and lung pathology",
            "Complete elimination of the virus from the bloodstream",
            "Increased weight gain and improved overall health",
            "No observable effect on viral replication or symptoms"
        ],
        "Which SARS-CoV-2 variants does NIH-CoVnb-112 demonstrate broad neutralization against?": [
            "Alpha, Beta, Gamma, and Delta",
            "Lambda, Mu, Eta, and Iota",
            "Zeta, Theta, Kappa, and Epsilon",
            "Omicron, Sigma, Tau, and Upsilon"
        ]
    }
}